WASHINGTON (AP) — President Donald Trump emphatically defended himself Tuesday against criticism from medical experts and others that his announced use of a malaria drug against the coronavirus could spark wide misuse by Americans of the unproven treatment with potentially fatal side effects.
Trump’s bland statement a day earlier that he was taking hydroxychloroquine caught many in his administration by surprise and set off an urgent effort by officials to justify his action. The government has warned that the drug should be administered for COVID-19 only in a hospital or research setting.
Trump decided to take hydroxychloroquine after two White House staffers tested positive for the disease, but he already had spent months promoting the drug as a potential cure or preventive despite the cautionary advice of many of his administration’s top medical professionals. The drug has the potential to cause significant side effects in some patients and has not been shown to combat the virus.
“This is an individual decision to make,” Trump told reporters during a visit to Capitol Hill Tuesday to huddle with Senate Republicans. “But it’s had a great reputation.”
Amid concerns from some public health experts that Trump’s example could send many more people to misuse the drug, White House press secretary Kayleigh McEnany said Tuesday that “tens of millions of people around the world have used this drug for other purposes,” including malaria prophylaxis. She emphasized, “You have to have a prescription. That’s the way it must be done.”
The drug is also prescribed for some lupus and arthritis patients.
Trump said his doctor did not recommend hydroxychloroquine to him, but that he requested it from the White House physician.
That physician, Dr. Sean Conley, said in a statement that, after “numerous discussions” with Trump, “we concluded the potential benefit from treatment outweighed the relative risks.”
The Food and Drug Administration warned health professionals last month that the drug should not be used to treat COVID-19 outside of hospital or research settings due to sometimes fatal side effects. Regulators issued the alert, in part, based on increased reports of dangerous side effects called in to U.S. poison control centers.
Calls to centers involving hydroxychloroquine increased last month to 96, compared with 49 in April 2019, according to data from the American Association of Poison Control Centers provided to the AP. It was the second month of elevated reports involving the drug, following 79 calls in March. The problems reported included abnormal heart rhythms, seizures, nausea and vomiting.
Trump dismissed reports of side effects, saying, “All I can tell you is, so far I seem to be OK.”
FDA Commissioner Stephen Hahn said in an emailed statement Tuesday: “The decision to take any drug is ultimately a decision between a patient and their doctor.”
Many studies are testing hydroxychloroquine for preventing or limiting coronavirus illness but “at this point in time there’s absolutely no evidence that this strategy works,” said Dr. Carlos del Rio, an infectious disease specialist at Emory University in Atlanta.
“My concern is, the president has a big bully pulpit … maybe people will think there’s some non-public evidence” that the drug works because Trump has chosen to use it, del Rio said. “It creates this conspiracy theory that something works and they’re not telling me about it yet.”
As research started to emerge that hydroxychloroquine was not helpful, and even potentially harmful, in battling COVID-19, the president’s public rhetoric in support of the drug had faded. But his private hopes had not, according to three White House officials and Republicans close to the White House not authorized to speak publicly about private discussions.
Trump alleged without evidence Tuesday that one government study that showed negative effects from the drug was meant to embarrass him.
“If you look at the one survey, the only bad survey, they were giving it to people that were in very bad shape,” Trump said. That was an apparent reference to a study of hundreds of patients treated by the Department of Veterans Affairs in which more people in a group who were administered hydroxychloroquine died than among those who weren’t.
“They were very old. Almost dead,” Trump said. “It was a Trump enemy statement.”
Senate Democratic leader Chuck Schumer questioned on MSNBC whether Trump was actually taking the drug and added, “I know him saying he is taking it, whether he is or not, is reckless, reckless, reckless.“
At least two White House staffers tested positive for COVID-19 earlier this month, sparking concerns about the steps taken by the administration to protect the president and sending Vice President Mike Pence and other officials into varying forms of self-isolation.
The White House has since mandated that those in the West Wing wear face coverings and has introduced daily testing for the virus for the president, vice president and those they come in close contact with. Trump says he continues to test negative for the coronavirus.
White House officials did not say whether any other administration officials were taking the drug.
Trump said he took hydroxychloroquine with an “original dose” of the antibiotic azithromycin. The president has repeatedly promoted the use of the drug with or without the azithromycin, but no large, rigorous studies have found them safe or effective for preventing or treating COVID-19.
Two large observational studies, each involving around 1,400 patients in New York, recently found no COVID benefit from hydroxychloroquine. Two new ones published Thursday in the medical journal BMJ reached the same conclusion.
Prescriptions for hydroxychloroquine surged roughly 80% in March to more than 830,000 compared with same period in the prior year, according to data tracking firm IQVIA. That jump in prescribing came before the federal government accepted nearly 30 million doses of the drug donated to the strategic national stockpile by foreign drugmakers. Since then, millions of those tablets have been shipped to U.S. hospitals nationwide for use treating patients with COVID-19.
Marchione reported from Milwaukee and Lemire reported from New York. AP writers Matthew Perrone and Darlene Superville in Washington contributed to this report.